HHS announced collaboration with Aegis Sciences for high quality rapid COVID-19 RT-PCR testing
On Aug. 13, 2020, the U.S. Department of Health and Human Services (HHS) announced combined investments of $6.5…
Bio-Techne announced new SARS-CoV-1/2 spike RBD LlaMABodyï¾™ recombinant antibody that blocks viral entry
On Aug. 11, 2020, Bio-Techne announced the release of the SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody, which binds…
Clinical trials of monoclonal antibodies to prevent COVID-19 began enrollment
On Aug. 10, 2020, two Phase 3, randomized, placebo-controlled, double-blind clinical trials testing whether experimental monoclonal antibodies (mAbs)…
IBIO-201 demonstrated ability to elicit anti-SARS-CoV-2 immune response in preclinical studies
On Aug. 10, 2020, iBio provided an update on one of its proprietary vaccine candidates being designed to…
Intravacc received US NIH/NIAID contract to develop Enterovirus D68 Vaccine
On Aug. 9, 2020, Intravacc announced that it had been awarded a contract with base and options that…
HKUMed discovered that acute SARS-CoV-2 infection impairs human immune defences
On Aug. 6, 2020, researchers at the AIDS Institute, Department of Microbiology and State Key Laboratory of Emerging…
NIH began clinical trial testing remdesivir plus interferon beta-1a for COVID-19 treatment
On Aug. 5, 2020, a randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen…
NIH-Moderna investigational COVID-19 vaccine showed promise in mouse studies
On Aug. 5, 2020, the National Institute of Allergy and Infectious Diseases (NIAID) announced that the investigational vaccine…
Heat Biologics highlighted Importance of T cell immunity to prevent COVID-19
On Aug. 5, 2020, Heat Biologics highlighted the importance of T cell immunity in preventing COVID-19 in a…
AXIM Biotechnologies applied for FDA Emergency Use Approval for high throughput, neutralizing antibody diagnostic test for COVID-19
On Aug. 5, 2020, AXIM Biotechnologies announced the development, patent filing and Emergency Use Approval (EUA) filing of…
VBI Vaccines awarded up to CAD$56 million contribution from Canadian Government to accelerate Coronavirus vaccine development
On Aug. 5, 2020, Variation Biotechnologies, an Ottawa-based subsidiary of VBI Vaccines, announced that it had been awarded…
CDC announced that 2020 outbreak of life-threatening acute flaccid myelitis expected
On Aug. 4, 2020, the CDC announced that it anticipated that 2020 will be another peak year for…
Innovation Pharma and US Regional Biocontainment Laboratory updated brilacidin anti-SARS-CoV-2 in vitro testing
On Aug. 4, 2020, Innovation Pharma reported receiving an update from a U.S. Regional Biocontainment Laboratory (RBL) based…
Cocrystal Pharma announced publication of positive data demonstrating potent in vitro inhibition against Coronavirus
On Aug. 4, 2020, Cocrystal Pharma announced the publication of preclinical animal studies of coronavirus antiviral compounds in…
La Jolla Institute for Immunology received $1 million from GHR Foundation in support of COVID-19 research
On Aug. 3, 2020, the La Jolla Institute for Immunology (LJI) announced a $1 million gift from GHR…
Lilly initiated phase 3 trial of LY-CoV555 for prevention of COVID-19 at lLong-term care facilities in partnership with NIAID
On Aug. 3, 2020, Eli Lilly announced the initiation of BLAZE-2, a phase 3 trial studying LY-CoV555 for…
NIH delivered new COVID-19 testing technologies to meet US demand
On Jul. 31, 2020, the NIH announced that it had invested $248.7 million in new technologies to address…
Single dose of Johnson & Johnson COVID-19 vaccine candidate demonstrated robust protection in pre-clinical studies
On Jul. 30, 2020, Johnson & Johnson announced that its lead vaccine candidate protected against infection with SARS-CoV-2,…
INOVIO’s COVID-19 DNA vaccine INO-4800 provided protection with memory immune responses In non-human primates challenged with SARS-CoV-2 virus
On Jul. 30, 2020, INOVIO announced that its COVID-19 DNA vaccine INO-4800 targeting SARS-CoV-2 was effective in protecting…
Veracyte and MAVIDx announcd agreement for MAVIDx to develop ultra-high volume COVID-19 testing on the nCounter System
On Jul. 29, 2020, Veracyte and MAVIDx announced an agreement for MAVIDx to develop ultra-high throughput genomic testing…
Heat Biologics COVID-19 vaccine demonstrated immunogenicity proof-of-concept in pre-clinical studies
On Jul. 29, 2020, Heat Biologics announced successful pre-clinical testing of the Company’s COVID-19 vaccine, which demonstrated in-vivo…
FDA authorized Quest Diagnostics lab method designed to increase COVID-19 molecular diagnostics capacity
On Jul. 29, 2020, Quest Diagnostics announced that the FDA had granted emergency use authorization for a new…
Experimental COVID-19 vaccine protected upper and lower airways in nonhuman primates
On Jul. 28, 2020, scientists at the National Institute of Allergy and Infectious Diseases reported that two doses…
Phase 3 clinical trial of investigational vaccine for COVID-19 began
On Jul. 27, 2020, the National Institutes of Health (NIH) announced that a phase 3 clinical trial designed…
Moderna announced phase 3 COVE study of mRNA vaccine against COVID-19 (mRNA-1273) began
On Jul. 27, 2020, Moderna announced that the Phase 3 study of its mRNA vaccine candidate (mRNA-1273) against…
Immunic announced first patients enrolled in investigator-sponsored phase 2 clinical trial of IMU-838 in combination with Oseltamivir for treatment of patients with COVID-19
On Jul. 27, 2020, Immunic announced enrollment of the first patients in an investigator-sponsored phase 2 clinical trial…
AXIM Biotechnologies released Rapid NeuCovix test results showing strong agreement with COVID-19-based neutralization tests
On Jul. 23, 2020, AXIM Biotechnologies announced development of NeuCovixTM, a rapid diagnostic test measuring levels of functional…
COVID-19 antibodies decay quickly after mild illness
On Jul. 22, 2020, University of California at Los Angeles researchers reported that they found. levels of antibodies…
Preclinical study showed SARS-CoV-2 spike protein licensed by Oragenics from NIH produces neutralizing antibodies
On Jul. 22, 2020, Oragenics announced that the National Institutes of Health created stabilized pre-fusion spike protein (CoV-2…
Experimental Coronavirus vaccine is safe and produced immune response
On Jul. 21, 2020, National Institutes of Health (NIH) researchers reported early results from the first COVID-19 vaccine…